Overview of the Market:
The Europe Diabetic Retinopathy Market has been estimated at USD 1.26 billion in 2018 and is projected to reach USD 1.73 billion by 2023, at a CAGR of 6.55% during the forecast period from 2018-2023. The European diabetic retinopathy market holds the highest share in the market, driven by rising patient awareness levels, particularly in the Western European countries. Europe market is geographically segmented into Spain, Germany, Italy, UK and France.
Diabetic retinopathy is a medical condition which damages retina and leads to blindness if untreated or undiagnosed. The degree of treatment of diabetic retinopathy varies according to various stages of the disease and is mainly prioritized to curb the disease at its initial stage.
Growth enhancing factors are government initiatives, abundant R&D activities, and skill set enhancement of healthcare providers. Such supportive initiatives coupled with rising awareness among patients are anticipated to result in lucrative growth. Treatment of diabetic retinopathy is expected to gain patients willingness for treatment by introducing advanced technology and reducing pain by using laser procedure with quick recovery time.
Geographical Analysis:
The Europe Diabetic Retinopathy Market has been segmented on the basis of indication into Non-Proliferative Diabetic Retinopathy (NPDR) and Proliferative Diabetic Retinopathy (PDR). NPDR is further sub segmented as Mild, Moderate and Severe. Based on Treatment type the market is bifurcated into Anti-Vascular Endothelial Growth Factor (VEGF) drug, Intraocular Steroid Injection, Laser Surgery and Vitrectomy. By end users division is among Hospitals, Ophthalmic Clinics and Ambulatory Surgical Centers. Non-proliferative retinopathy dominated the overall market size estimated to lead the market. Augmented incidence of diabetes, lack of diagnosis at right time, and non-compliant retinal screening of diabetic patients are predicted to propel the growth of non-proliferative diabetic retinopathy market share.
Key Players in this Market:
The Major companies in Diabetic Retinopathy treatment market are Bayer AG, Pfizer Inc., Hoffmann-La Roche ltd, Regeneron Pharmaceutical Inc., Novartis AG, Valeant Pharmaceutical International Inc., Abbott Laboratories Inc., Alimera Science Inc. and Ampio Pharmaceuticals Inc.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type of Treatment
5.1.1 Anti-Vascular Endothelial Growth Factor (VEGF) drug
5.1.2 Intraocular Steroid Injection
5.1.3 Laser Surgery
5.1.4 Vitrectomy
5.2 By Indication
5.2.1 Non-Proliferative Diabetic Retinopathy (NPDR)
5.2.1.1 Mild
5.2.1.2 Moderate
5.2.1.3 Severe
5.2.2 Proliferative Diabetic Retinopathy (PDR)
5.3 By End Users
5.3.1 Hospitals
5.3.2 Ophthalmic Clinics
5.3.3 Ambulatory Surgical Centers
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Bayer AG
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Pfizer Inc.
8.3 Hoffmann-La Roche ltd
8.4 Regeneron Pharmaceutical Inc.
8.5 Novartis AG
8.6 Valeant Pharmaceutical International Inc.
8.7 Abbott Laboratories Inc.
8.8 Alimera Science Inc.
8.9 Ampio Pharmaceuticals Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
